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Impact of COVID-19 on 
people with cystic 
fibrosis
Early and detailed characterisation of 
coronavirus disease 2019 (COVID-19) 
has emerged principally through 
publications from China, where the 
disease was first identified.1 As the 
pandemic spread to Lombardia, 
Northern Italy and then globally,2 
evaluating the impact on people 
with cystic fibrosis has become 
imperative, because the prevalence 
of this inherited condition is much 
higher in populations derived from 
Europe than in other populations.3 
Since the beginning of the outbreak 
in Lombardia, severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
infections have been reported in ten 
patients with cystic fibrosis out of 
42 161 people in the region known 
to have been infected. The number 
of infected patients in Lombardia 
make up a substantial proportion 
of the 101 739 total SARS-CoV-2 
infections in Italy (according to 
available data on March 31, 2020). 
The Italian patients with cystic fibrosis 
were resident in endemic areas and 
acquired the infection from family 
members. These observations, as well 
as data from other European countries 
(five patients with cystic fibrosis in 
France have been reported to have 
SARS-CoV-2 infection, seven in the 
UK, five in Germany and three [one 
transplanted] in Spain) suggest few 
patients with cystic fibrosis, mainly 
adults, are becoming infected with 
SARS-CoV-19, without apparent effect 
on cystic fibrosis disease severity. From 
these data, it is not possible to identify 
factors that might be protective, for 
example use of long-term antibiotic 
therapy such as azithromycin.
The few reported cases of 
SARS-CoV-2 infection in people 
with cystic fibrosis might reflect the 
efforts of families across Europe to 
minimise social contacts. This effort 
might be considered a success, but 
there is no room for complacency and 
the directive for social shielding of 
both the patient and family members 
remains clear and important.
More data should be collected to 
better characterise the impact of 
COVID-19 on patients with cystic 
fibrosis. The European Cystic Fibrosis 
Society (ECFS) is supporting the 
collection and timely sharing of data 
from across Europe. The ECFS Patient 
Registry, in cooperation with national 
cystic fibrosis registries, has established 
a data collection and reporting system, 
contributing to an international 
harmonised dataset, to identify factors 
that predict severity of COVID-19.
Viral respiratory tract infections are 
more severe in patients with cystic 
fibrosis than in the general population, 
with an increased risk of complications 
and a negative impact on lung 
function. During the 2009 influenza 
pandemic, H1N1 virus caused sub-
stantial morbidity in patients with 
cystic fibrosis, and in a subgroup with 
severe lung disease, H1N1 infection 
was associated with respiratory 
deterioration, mechanical ventilation, 
and even death.4,5
The situation in Italy has been 
monitored carefully to inform 
management strategies and provide 
clear advice for patients with cystic 
fibrosis and their families. Consistent 
with the Italian Government, the Cystic 
Fibrosis Center in Milan promptly 
recommended self-isolation for 
these patients. Recommendations 
for preventive measures that were 
already established in this population, 
such as using face masks and 
practising adequate hand hygiene, 
were reinforced. The cystic fibrosis 
team in Milan cancelled routine clinic 
appointments to prevent unnecessary 
hospital visits and viral spread. 
Procedures such as respiratory function 
testing and bronchoscopy were put on 
hold. Phone calls and email contacts 
were used to monitor the clinical 
condition of patients and to provide 
psychological support immediately 
after the lockdown.
These measures have subsequently 
been adopted by cystic fibrosis centres 
across Europe. There is no doubt 
that cancelling routine cystic fibrosis 
clinics and monitoring according to 
ECFS standards of care3 will have a 
negative impact on the wellbeing of 
patients with cystic fibrosis over time. 
It is important that patients and their 
families are provided with tools to 
support self-monitoring during this 
period. This self-monitoring might 
include transmission to clinicians of 
spirometry and oxygen saturation data 
that are recorded at home. Support 
should also include the capacity to 
carry out respiratory culture at home 
and send to the laboratory securely.
Home visits by health-care pro-
fessionals present a risk of SARS-CoV-2 
transmission and virtual clinics should 
be used to provide families with 
advice on all aspects of cystic fibrosis 
care management, including airway 
clearance and maintaining exercise. In 
case cystic fibrosis team members are 
seconded to work on the front line of 
tackling this pandemic, it is imperative 
that lines of communication remain 
open and that patients with cystic 
fibrosis do not feel isolated. For 
patients with more severe cystic 
fibrosis, access to lung transplantation 
might be compromised.
People with cystic fibrosis have a 
phenotypic spectrum ranging from 
excellent respiratory health to chronic 
airways disease with productive 
cough and respiratory compromise. 
The clinical features of COVID-19 (dry 
cough, myalgia, and fever) are quite 
distinct from the symptoms of cystic 
fibrosis. Therefore, most COVID-19 
in people with cystic fibrosis should 
be recognisable, but it is possible 
that mild disease might be labelled 
as within the normal spectrum of 
symptoms for that individual. A low 
threshold for testing is therefore 
needed in this population.
Many isolated families are concerned 
about collection of medicines and food 
during this pandemic. Most countries 
have established systems to ensure 
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People with cystic fibrosis and their 
families have invested considerable 
time and energy to maintain good 
health and, now, on the cusp of 
remarkable new therapies to transform 
their condition, they face a global 
pandemic, the effect of which is 
unclear. Early data suggest that most 
patients with cystic fibrosis are doing 
an exceptional job avoiding SARS-
CoV-19 infection, but they must 
remain dedicated to this task, as data 
are gathered from across Europe to 
better understand factors that affect 
the severity of COVID-19 in people with 
cystic fibrosis.
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deliveries to people who are isolated, 
often using volunteers, but as the 
pandemic progresses, maintaining 
these systems will be a priority for 
patients with cystic fibrosis and their 
families. A further concern is the halt 
to the development of new therapies 
for cystic fibrosis.3 No new clinical 
trials are being initiated in Europe and 
recruitment of patients to ongoing trials 
is being stopped. Patients in existing 
trials are being supported by reducing 
study visits with the agreement of 
regulatory bodies such as the European 
Medicines Agency and by providing 
study medication to the home.6
As national advice changes rapidly 
to respond to the pandemic, it 
is important that cystic fibrosis 
organisations place this advice in 
context and present information for 
patients and their families that is based 
on clear evidence and not conjecture.
This pandemic is imposing an 
extraordinary level of stress on health 
services and the consequences include 
the trauma of witnessing so many 
deaths, even of young and healthy 
people, and the impact on the whole 
community of fear, isolation, and 
uncertainty for the future. Following 
the situation in Italy, a community-
oriented plan for the next pandemic is 
clearly needed.7
